Skip to main content
Top
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Hepatocellular Carcinoma | Primary research

Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p

Authors: Zhiqin Li, Yushu Hu, Qinglei Zeng, Hongyan Wang, Jingya Yan, Hua Li, Zujiang Yu

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

CircRNA myosin light chain kinase (circRNA MYLK) has been shown to promote the progression of various tumor diseases. The purpose of this study was to explore the potential molecular mechanism of circMYLK in hepatocellular carcinoma (HCC).

Methods

The quantitative Real-Time PCR (qRT-PCR) was used to measure the expressions of circMYLK, miR-362-3p and Rab23 in HCC tissues and cell lines. Huh7 and Hep3B cells were selected to explore the role of circMYLK in proliferation, invasion and migration of HCC cells in vitro. The interaction among circMYLK, miR-362-3p and Rab23 was investigated by biological information and dual luciferase gene reporter assay. The effect of circMYLK on HCC tumor growth in vivo was studied in a tumor xenograft model in mice.

Results

CircMYLK was highly expressed in HCC tissues and cell lines, which was associated with poor prognosis in HCC patients. In addition, knockdown of circMYLK remarkably inhibited the proliferation, invasion, and migration of Huh7 and Hep3B cells. MiR-362-3p was a direct target of circMYLK, and Rab23 was a direct target gene of miR-362-3p. Meanwhile, circMYLK was negatively correlated with the expression of miR-362-3p and positively correlated with Rab23 expression. Moreover, either overexpressed miR-362-3p or silencing Rab23 could observably suppress the enhanced proliferation, invasion, and migration induced by circMYLK in Huh7 and Hep3B cells. Finally, knockdown of circMYLK and overexpressed miR-362-3p could suppress the expression of Rab23, thus inhibiting the growth and proliferation of Hep3B cells in vivo.

Conclusion

circMYLK promotes the occurrence and development of HCC by regulating the miR-362-3p/Rab23 axis, which provides a novel direction and theoretical basis for the early diagnosis and treatment of HCC.
Literature
1.
go back to reference Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.CrossRef Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.CrossRef
2.
go back to reference Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753–70.CrossRef Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753–70.CrossRef
3.
go back to reference Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.CrossRef Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.CrossRef
4.
go back to reference Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRef Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.CrossRef
5.
go back to reference Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550.CrossRef Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550.CrossRef
6.
go back to reference Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef
7.
go back to reference Balogh J, David Victor EHA III, Burroughs SG, Boktour M, Saharia A, Li X, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41.CrossRef Balogh J, David Victor EHA III, Burroughs SG, Boktour M, Saharia A, Li X, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41.CrossRef
8.
go back to reference Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of circRNAs. Mol Cell. 2017;66(1):9.e7–21.e7.CrossRef Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of circRNAs. Mol Cell. 2017;66(1):9.e7–21.e7.CrossRef
9.
go back to reference Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(5):309–16.CrossRef Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(5):309–16.CrossRef
10.
go back to reference Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141–8.CrossRef Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141–8.CrossRef
11.
go back to reference Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol. 2017;11(4):422–37.CrossRef Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol. 2017;11(4):422–37.CrossRef
12.
go back to reference Fu L, Yao T, Chen Q, Mo X, Hu Y, Guo J. Screening differential circular RNA expression profiles reveals hsa_circ_0004018 is associated with hepatocellular carcinoma. Oncotarget. 2017;8(35):58405.PubMedPubMedCentral Fu L, Yao T, Chen Q, Mo X, Hu Y, Guo J. Screening differential circular RNA expression profiles reveals hsa_circ_0004018 is associated with hepatocellular carcinoma. Oncotarget. 2017;8(35):58405.PubMedPubMedCentral
13.
go back to reference Zhong Z, Huang M, Lv M, He Y, Duan C, Zhang L, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;403:305–17.CrossRef Zhong Z, Huang M, Lv M, He Y, Duan C, Zhang L, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;403:305–17.CrossRef
14.
go back to reference Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, et al. Circular rna myosin light chain kinase (mylk) promotes prostate cancer progression through modulating mir-29a expression. Med Sci Monit. 2018;24:3462.CrossRef Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, et al. Circular rna myosin light chain kinase (mylk) promotes prostate cancer progression through modulating mir-29a expression. Med Sci Monit. 2018;24:3462.CrossRef
15.
go back to reference Luo B, Tang CM, Chen JS. circRNA and gastrointestinal cancer. J Cell Biochem. 2019;120(7):10956–63.CrossRef Luo B, Tang CM, Chen JS. circRNA and gastrointestinal cancer. J Cell Biochem. 2019;120(7):10956–63.CrossRef
16.
go back to reference Rong D, Sun H, Li Z, Liu S, Dong C, Fu K, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017;8(42):73271.CrossRef Rong D, Sun H, Li Z, Liu S, Dong C, Fu K, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017;8(42):73271.CrossRef
17.
go back to reference Iwakawa H-O, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol. 2015;25(11):651–65.CrossRef Iwakawa H-O, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol. 2015;25(11):651–65.CrossRef
18.
go back to reference Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42.CrossRef Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42.CrossRef
19.
go back to reference Augello C, Colombo F, Terrasi A, Trombetta E, Maggioni M, Porretti L, et al. Expression of C19MC miRNAs in HCC associates with stem-cell features and the cancer-testis genes signature. Dig Liver Dis. 2018;50(6):583–93.CrossRef Augello C, Colombo F, Terrasi A, Trombetta E, Maggioni M, Porretti L, et al. Expression of C19MC miRNAs in HCC associates with stem-cell features and the cancer-testis genes signature. Dig Liver Dis. 2018;50(6):583–93.CrossRef
20.
go back to reference Nayak B, Nadda N, Yadav D, Paul SB, Acharya SK. Differential expression of circulating miRNAs among healthy, diseased controls and HCC patients—pilot study. J Clin Exp Hepatol. 2016;6:S66–7.CrossRef Nayak B, Nadda N, Yadav D, Paul SB, Acharya SK. Differential expression of circulating miRNAs among healthy, diseased controls and HCC patients—pilot study. J Clin Exp Hepatol. 2016;6:S66–7.CrossRef
21.
go back to reference Zou X, Zhong J, Li J, Su Z, Chen Y, Deng W, et al. miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells. Mol Med Rep. 2016;13(1):994–1002.CrossRef Zou X, Zhong J, Li J, Su Z, Chen Y, Deng W, et al. miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells. Mol Med Rep. 2016;13(1):994–1002.CrossRef
22.
go back to reference Shen H, Li W, Tian Y, Xu P, Wang H, Zhang J, et al. Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma. J Cell Biochem. 2015;116(8):1563–73.CrossRef Shen H, Li W, Tian Y, Xu P, Wang H, Zhang J, et al. Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma. J Cell Biochem. 2015;116(8):1563–73.CrossRef
24.
go back to reference Chen R, Xia W, Wang S, Xu Y, Ma Z, Xu W, et al. Long noncoding RNA SBF2-AS1 Is critical for tumorigenesis of early-stage lung adenocarcinoma. Mol Ther Nucleic Acids. 2019;16:543–53.CrossRef Chen R, Xia W, Wang S, Xu Y, Ma Z, Xu W, et al. Long noncoding RNA SBF2-AS1 Is critical for tumorigenesis of early-stage lung adenocarcinoma. Mol Ther Nucleic Acids. 2019;16:543–53.CrossRef
25.
go back to reference Hor CH, Tang BL, Goh EL. Rab23 and developmental disorders. Rev Neurosci. 2018;29(8):849–60.CrossRef Hor CH, Tang BL, Goh EL. Rab23 and developmental disorders. Rev Neurosci. 2018;29(8):849–60.CrossRef
26.
go back to reference Zhang W, Yu F, Wang Y, Zhang Y, Meng L, Chi Y. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway. Oncol Lett. 2018;15(4):5155–60.PubMedPubMedCentral Zhang W, Yu F, Wang Y, Zhang Y, Meng L, Chi Y. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway. Oncol Lett. 2018;15(4):5155–60.PubMedPubMedCentral
27.
go back to reference Chen Y, Ng F, Tang BL. Rab23 activities and human cancer—emerging connections and mechanisms. Tumor Biol. 2016;37(10):12959–67.CrossRef Chen Y, Ng F, Tang BL. Rab23 activities and human cancer—emerging connections and mechanisms. Tumor Biol. 2016;37(10):12959–67.CrossRef
28.
go back to reference Wang Y, Qin H. miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018;8(12):2564.PubMedPubMedCentral Wang Y, Qin H. miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018;8(12):2564.PubMedPubMedCentral
29.
go back to reference Chang J, Xu W, Liu G, Du X, Li X. Downregulation of Rab23 in prostate cancer inhibits tumor growth in vitro and in vivo. Oncol Res Featur Preclin Clin Cancer Ther. 2017;25(2):241–8. Chang J, Xu W, Liu G, Du X, Li X. Downregulation of Rab23 in prostate cancer inhibits tumor growth in vitro and in vivo. Oncol Res Featur Preclin Clin Cancer Ther. 2017;25(2):241–8.
30.
go back to reference Cooper EA, Reddy S, Allenson AZ, Cooper DP, Fowler PA, Rae MT, et al., QRT-PCR analysis of the effect of in utero exposure to sewage sludge on steroidogenic gene expression in ovine foetal adrenal gland. Presented at Society for Endocrinology BES 2018, Glasgow, UK. Endocrine Abstracts. 2018; 59: P038. https://www.endocrine-abstracts.org/ea/0059/ea0059p038 Cooper EA, Reddy S, Allenson AZ, Cooper DP, Fowler PA, Rae MT, et al., QRT-PCR analysis of the effect of in utero exposure to sewage sludge on steroidogenic gene expression in ovine foetal adrenal gland. Presented at Society for Endocrinology BES 2018, Glasgow, UK. Endocrine Abstracts. 2018; 59: P038. https://​www.​endocrine-abstracts.​org/​ea/​0059/​ea0059p038
31.
go back to reference Peng L, Chen G, Zhu Z, Shen Z, Du C, Zang R, et al. Circular RNA ZNF609 functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-150-5p in Hirschsprung’s disease. Oncotarget. 2017;8(1):808.PubMed Peng L, Chen G, Zhu Z, Shen Z, Du C, Zang R, et al. Circular RNA ZNF609 functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-150-5p in Hirschsprung’s disease. Oncotarget. 2017;8(1):808.PubMed
32.
go back to reference Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016;12(5):3045–50.CrossRef Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016;12(5):3045–50.CrossRef
33.
go back to reference Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, et al. Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(5):933–9.CrossRef Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, et al. Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(5):933–9.CrossRef
34.
go back to reference Liang W-C, Wong C-W, Liang P-P, Shi M, Cao Y, Rao S-T, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20(1):84.CrossRef Liang W-C, Wong C-W, Liang P-P, Shi M, Cao Y, Rao S-T, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20(1):84.CrossRef
35.
go back to reference Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272.CrossRef Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272.CrossRef
36.
go back to reference Liang H-F, Zhang X-Z, Liu B-G, Jia G-T, Li W-L. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J Cancer Res. 2017;7(7):1566.PubMedPubMedCentral Liang H-F, Zhang X-Z, Liu B-G, Jia G-T, Li W-L. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J Cancer Res. 2017;7(7):1566.PubMedPubMedCentral
37.
go back to reference Lu L-F, Gasteiger G, Yu I-S, Chaudhry A, Hsin J-P, Lu Y, et al. A single miRNA-mRNA interaction affects the immune response in a context-and cell-type-specific manner. Immunity. 2015;43(1):52–64.CrossRef Lu L-F, Gasteiger G, Yu I-S, Chaudhry A, Hsin J-P, Lu Y, et al. A single miRNA-mRNA interaction affects the immune response in a context-and cell-type-specific manner. Immunity. 2015;43(1):52–64.CrossRef
38.
go back to reference Cloonan N. Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery. BioEssays. 2015;37(4):379–88.CrossRef Cloonan N. Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery. BioEssays. 2015;37(4):379–88.CrossRef
39.
go back to reference Wang M, Dong Q, Wang Y. Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1. Tumor Biol. 2016;37(8):11049–55.CrossRef Wang M, Dong Q, Wang Y. Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1. Tumor Biol. 2016;37(8):11049–55.CrossRef
41.
go back to reference Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13–22.CrossRef Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13–22.CrossRef
42.
go back to reference Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA Cdr1as act as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS ONE. 2016;11(7):e0158347.CrossRef Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA Cdr1as act as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS ONE. 2016;11(7):e0158347.CrossRef
Metadata
Title
Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p
Authors
Zhiqin Li
Yushu Hu
Qinglei Zeng
Hongyan Wang
Jingya Yan
Hua Li
Zujiang Yu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0926-7

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine